Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783399 | 0.83 | PDK2 (0.38) | KDM4EHSD17B10LMNA | |
| SCHEMBL19087065 | 0.83 | — | — | |
| SCHEMBL3690726 | 0.81 | KDM4E (0.31) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL7969215 | 0.78 | HSD17B10 (0.34) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL3697296 | 0.78 | SMPD3 (0.36) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL22268030 | 0.77 | TOP2A (0.32) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL3698711 | 0.72 | — | — | |
| SCHEMBL3787517 | 0.72 | KDM4E (0.35) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL6855320 | 0.70 | ADORA1 (0.43) | — | |
| SCHEMBL798499 | 0.70 | KDM4E (0.34) | KDM4EHSD17B10LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-9018387-B2 | Complexes of imidazole ligands | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-8680289-B2 | Complexes of imidazole ligands | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2580223-A1 | COMPLEXES OF IMIDAZOLE LIGANDS | Air Products and Chemicals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20130078391-A1 | Complexes Of Imidazole Ligands | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20120121806-A1 | Complexes Of Imidazole Ligands | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011156699-A1 | COMPLEXES OF IMIDAZOLE LIGANDS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078391-A1 | Complexes Of Imidazole Ligands | ICOSLG, CLTC, PICALM | KDM4E 2146/4885HSD17B10 4568/4885LMNA 2718/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | KDM4E 2506/4885HSD17B10 3403/4885LMNA 3680/4885 |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | KDM4E 2506/4885HSD17B10 3403/4885LMNA 3680/4885 |
| US-20120121806-A1 | Complexes Of Imidazole Ligands | ICOSLG, CLTC, PICALM | KDM4E 2146/4885HSD17B10 4568/4885LMNA 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.